NCT07437963 2026-03-18
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
National Cancer Institute (NCI)
Phase 1/2 Not yet recruiting
Clinical Trials
27 trialsNCT05269381 2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2 Recruiting
NCT06626516 2025-11-28
Tebentafusp-tebn With LDT in Metastatic UM
Thomas Jefferson University
Phase 1/2 Recruiting
NCT04211675 2025-05-13
STING
Nationwide Children's Hospital
Phase 1/2 Recruiting
NCT01784913 2024-12-16
UV1/hTERT2012P
Ultimovacs ASA
Phase 1/2 Completed
NCT01789099 2024-12-16
UV1-hTERT2012L
Ultimovacs ASA
Phase 1/2 Completed
NCT02275416 2024-12-16
Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma
Ultimovacs ASA
Phase 1/2 Completed
NCT03761914 2024-11-19
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
Sellas Life Sciences Group
Phase 1/2 Completed
NCT01827137 2024-09-19
WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation
Sellas Life Sciences Group
Phase 1/2 Completed
NCT05101356 2024-05-21
A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma
University of California, Davis
Phase 1/2 Recruiting
NCT00002950 2020-08-17
Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer
Yale University
Phase 1/2 Completed
NCT01580696 2020-05-04
Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer
San Antonio Military Medical Center
Phase 1/2 Completed
NCT01355393 2020-02-10
Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer
University of Washington
Phase 1/2 Completed
NCT00088413 2019-04-16
PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT03282188 2018-05-04
REO13 Melanoma With of Without GM-CSF
University of Leeds
Phase 1/2 Withdrawn
NCT00791037 2017-05-25
Vaccine Therapy in Treating Patients With Stage IV Breast Cancer
University of Washington
Phase 1/2 Completed
NCT00089219 2014-11-20
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma
University of Virginia
Phase 1/2 Completed
NCT00002817 2014-01-10
Vaccine Therapy in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00002780 2013-12-19
Biological Therapy in Treating Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00030342 2013-06-26
Biological Therapy and Chemotherapy in Treating Patients With Metastatic Kidney Cancer or Colorectal Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00785122 2013-05-16
IMA910-101
Immatics Biotechnologies GmbH
Phase 1/2 Completed
NCT00004184 2013-04-12
Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma
University of Alabama at Birmingham
Phase 1/2 Completed
NCT00939510 2013-01-31
Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT00004918 2013-01-07
Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00048893 2012-04-13
Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01527422 2012-02-07
CHOP-R
Auxilio Mutuo Cancer Center
Phase 1/2 Completed
NCT00602706 2011-05-16
Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant
Mayo Clinic
Phase 1/2 Completed